Drugs Health Pharma

Merck to buy Terns for $6.7 billion as Keytruda drug patent loss looms

Merck & Co will buy Terns Pharmaceuticals, Inc., a clinical-stage oncology company, for $6.7 billion to pocket an investigational drug to treat a.

Read More